To delve deeper into the in vivo anti-tumor efficacy of WIP2W and M—WIP2W, WT1+ BP-CML mice received daily treatments of PBS, imatinib, WIP2W, and M—WIP2W for two weeks. The gene discussed is WT1; the disease is neoplasm.